RESUMEN
Among untreated HIV-infected pregnant women, the frequency of mother-to-child transmission of HIV is low (5-10%), with most infections occurring at or after birth. Given findings that fetal and adult monocytes are distinct from one another in terms of basal transcriptional profiles, and in phosphorylation of signal transducer and activators of transcription in response to cytokines, we hypothesized that fetal CD14+CD16- monocyte and monocyte-derived macrophages (MDMs) might, compared to their adult counterparts, express higher levels of transcripts for restriction factors and antiviral factors at baseline and/or after stimulation with cytokines that might be induced upon transmission of HIV in utero, for example, IFNα, IFNγ, and IL-6. We carried out these experiments and noted that a few genes, including APOBEC3B, APOBEC3C, and IFITM2, were expressed to a greater degree in fetal monocytes compared to adults. Similarly, the expression levels of APOBEC3F and TRIM32 were greater in fetal MDMs. However, most of these differences were not observed after stimulation with cytokines and the vast majority of antiviral genes were more highly expressed in adults. Therefore, the results of this study are not consistent with the hypothesis that increased expression of antiviral genes in fetal myeloid cells confers immune protection to fetuses in utero.
Asunto(s)
Perfilación de la Expresión Génica , VIH/inmunología , Factores Inmunológicos/biosíntesis , Macrófagos/inmunología , Monocitos/inmunología , ARN Mensajero/análisis , Adulto , Células Cultivadas , Femenino , Feto , Infecciones por VIH/inmunología , Humanos , Embarazo , Complicaciones Infecciosas del Embarazo/inmunologíaRESUMEN
Recovery from Friend virus 3 (Rfv3) is a single autosomal gene encoding a resistance trait that influences retroviral neutralizing antibody responses and viremia. Despite extensive research for 30 years, the molecular identity of Rfv3 has remained elusive. Here, we demonstrate that Rfv3 is encoded by Apobec3. Apobec3 maps to the same chromosome region as Rfv3 and has broad inhibitory activity against retroviruses, including HIV. Not only did genetic inactivation of Apobec3 convert Rfv3-resistant mice to a susceptible phenotype, but Apobec3 was also found to be naturally disabled by aberrant messenger RNA splicing in Rfv3-susceptible strains. The link between Apobec3 and neutralizing antibody responses highlights an Apobec3-dependent mechanism of host protection that might extend to HIV and other human retroviral infections.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Citidina Desaminasa/genética , Virus de la Leucemia Murina de Friend/inmunología , Infecciones por Retroviridae/inmunología , Infecciones Tumorales por Virus/inmunología , Animales , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Mapeo Cromosómico , Clonación Molecular , Citidina Desaminasa/metabolismo , Virus de la Leucemia Murina de Friend/fisiología , Inmunidad Innata , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Pruebas de Neutralización , Infecciones por Retroviridae/genética , Infecciones por Retroviridae/virología , Infecciones Tumorales por Virus/genética , Infecciones Tumorales por Virus/virología , ViremiaRESUMEN
There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5alpha, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.
Asunto(s)
Fármacos Anti-VIH/farmacología , Infecciones por VIH/tratamiento farmacológico , VIH/efectos de los fármacos , Desaminasa APOBEC-3G , Proteínas Adaptadoras Transductoras de Señales/antagonistas & inhibidores , Animales , Factores de Restricción Antivirales , Proteínas Portadoras/antagonistas & inhibidores , Citidina Desaminasa/antagonistas & inhibidores , VIH/fisiología , Infecciones por VIH/virología , Proteínas del Virus de la Inmunodeficiencia Humana/antagonistas & inhibidores , Humanos , Factores de Transcripción/antagonistas & inhibidores , Proteínas de Motivos Tripartitos , Ubiquitina-Proteína Ligasas , Proteínas Reguladoras y Accesorias Virales/antagonistas & inhibidoresRESUMEN
APOBEC3G (A3G) is a potent antiretroviral deoxycytidine deaminase that, when incorporated into HIV virions, hypermutates nascent viral DNA formed during reverse transcription. HIV Vif counters the effect of A3G by depleting intracellular stores of the enzyme, thereby blocking its virion incorporation. Through pulse-chase analyses, we demonstrate that virion A3G is mainly recruited from the cellular pool of newly synthesized enzyme compared to older "mature" A3G already residing in high-molecular-mass RNA-protein complexes. Virion-incorporated A3G forms a large complex with viral genomic RNA that is clearly distinct from cellular HMM A3G complexes, as revealed by both gel filtration and biochemical fractionation. Unexpectedly, the enzymatic activity of virion-incorporated A3G is lost upon its stable association with HIV RNA. The activity of the latent A3G enzyme is ultimately restored during reverse transcription by the action of HIV RNase H. Degradation of the viral genomic RNA by RNase H not only generates the minus-strand DNA substrate targeted by A3G for hypermutation but also removes the inhibitory RNA bound to A3G, thereby enabling its function as a deoxycytidine deaminase. These findings highlight an unexpected interplay between host and virus where initiation of antiviral enzymatic activity is dependent on the action of an essential viral enzyme.
Asunto(s)
VIH/metabolismo , Nucleósido Desaminasas/fisiología , ARN Viral/metabolismo , Proteínas Represoras/fisiología , Ribonucleasa H/metabolismo , Virión/metabolismo , Desaminasa APOBEC-3G , Citidina Desaminasa , Activación Enzimática , Productos del Gen vif/fisiología , VIH/genética , Humanos , Nucleósido Desaminasas/antagonistas & inhibidores , Proteínas Represoras/antagonistas & inhibidores , Transcripción Genética , Ensamble de Virus , Productos del Gen vif del Virus de la Inmunodeficiencia HumanaRESUMEN
Human immunodeficiency virus (HIV) can infect resting CD4 T cells residing in lymphoid tissues but not those circulating in peripheral blood. The molecular mechanisms producing this difference remain unknown. We explored the potential role of the tissue microenvironment and its influence on the action of the antiviral factor APOBEC3G (A3G) in regulating permissivity to HIV infection. We found that endogenous IL-2 and -15 play a key role in rendering resident naive CD4 T cells susceptible to HIV infection. Infection of memory CD4 T cells also requires endogenous soluble factors, but not IL-2 or -15. A3G is found in a high molecular mass complex in HIV infection-permissive, tissue-resident naive CD4 T cells but resides in a low molecular mass form in nonpermissive, blood-derived naive CD4 T cells. Upon treatment with endogenous soluble factors, these cells become permissive for HIV infection, as low molecular mass A3G is induced to assemble into high molecular mass complexes. These findings suggest that in lymphoid tissues, endogenous soluble factors, likely including IL-2 and -15 and others, stimulate the formation of high molecular mass A3G complexes in tissue-resident naive CD4 T cells, thereby relieving the potent postentry restriction block for HIV infection conferred by low molecular mass A3G.
Asunto(s)
Linfocitos T CD4-Positivos/virología , Infecciones por VIH/metabolismo , Nucleósido Desaminasas/metabolismo , Proteínas Represoras/metabolismo , Desaminasa APOBEC-3G , Células Cultivadas , Medios de Cultivo Condicionados , Citidina Desaminasa , Humanos , Interleucina-15/fisiología , Interleucina-2/fisiología , Peso Molecular , Tonsila Palatina/citología , Tonsila Palatina/metabolismo , Tonsila Palatina/virologíaRESUMEN
The HIV-1 protein Nef enhances viral pathogenicity and accelerates disease progression in vivo. Nef potentiates T cell activation by an unknown mechanism, probably by optimizing the intracellular environment for HIV replication. Using a new T cell reporter system, we have found that Nef more than doubles the number of cells expressing the transcription factors NF-kappaB and NFAT after TCR stimulation. This Nef-induced priming of TCR signaling pathways occurred independently of calcium signaling and involved a very proximal step before protein kinase C activation. Engagement of the TCR by MHC-bound Ag triggers the formation of the immunological synapse by recruiting detergent-resistant membrane microdomains, termed lipid rafts. Approximately 5-10% of the total cellular pool of Nef is localized within lipid rafts. Using confocal and real-time microscopy, we found that Nef in lipid rafts was recruited into the immunological synapse within minutes after Ab engagement of the TCR/CD3 and CD28 receptors. This recruitment was dependent on the N-terminal domain of Nef encompassing its myristoylation. Nef did not increase the number of cell surface lipid rafts or immunological synapses. Recently, studies have shown a specific interaction of Nef with an active subpopulation of p21-activated kinase-2 found only in the lipid rafts. Thus, the corecruitment of Nef and key cellular partners (e.g., activated p21-activated kinase-2) into the immunological synapse may underlie the increased frequency of cells expressing transcriptionally active forms of NF-kappaB and NFAT and the resultant changes in T cell activation.
Asunto(s)
Productos del Gen nef/fisiología , VIH/fisiología , Activación de Linfocitos , Microdominios de Membrana/metabolismo , Receptores de Antígenos de Linfocitos T/fisiología , Linfocitos T/inmunología , Antígenos CD28/fisiología , Señalización del Calcio , Productos del Gen nef/química , Humanos , Células Jurkat , FN-kappa B/metabolismo , Factores de Transcripción NFATC/metabolismo , Proteína Quinasa C/fisiología , Proteínas Serina-Treonina Quinasas/fisiología , Estructura Terciaria de Proteína , Productos del Gen nef del Virus de la Inmunodeficiencia Humana , Quinasas p21 ActivadasRESUMEN
In contrast to activated CD4+ T cells, resting human CD4+ T cells circulating in blood are highly resistant to infection with human immunodeficiency virus (HIV). Whether the inability of HIV to infect these resting CD4+ T cells is due to the lack of a key factor, or alternatively reflects the presence of an efficient mechanism for defence against HIV, is not clear. Here we show that the anti-retroviral deoxycytidine deaminase APOBEC3G strongly protects unstimulated peripheral blood CD4+ T cells against HIV-1 infection. In activated CD4+ T cells, cytoplasmic APOBEC3G resides in an enzymatically inactive, high-molecular-mass (HMM) ribonucleoprotein complex that converts to an enzymatically active low-molecular-mass (LMM) form after treatment with RNase. In contrast, LMM APOBEC3G predominates in unstimulated CD4+ T cells, where HIV-1 replication is blocked and reverse transcription is impaired. Mitogen activation induces the recruitment of LMM APOBEC3G into the HMM complex, and this correlates with a sharp increase in permissivity for HIV infection in these stimulated cells. Notably, when APOBEC3G-specific small interfering RNAs are introduced into unstimulated CD4+ T cells, the early replication block encountered by HIV-1 is greatly relieved. Thus, LMM APOBEC3G functions as a potent post-entry restriction factor for HIV-1 in unstimulated CD4+ T cells. Surprisingly, sequencing of the reverse transcripts slowly formed in unstimulated CD4+ T cells reveals only low levels of dG dA hypermutation, raising the possibility that the APOBEC3G-restricting activity may not be strictly dependent on deoxycytidine deamination
Asunto(s)
Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/virología , Infecciones por VIH/metabolismo , VIH-1/fisiología , Proteínas/metabolismo , Desaminasa APOBEC-3G , Secuencia de Aminoácidos , Secuencia de Bases , Linfocitos T CD4-Positivos/enzimología , Linfocitos T CD4-Positivos/metabolismo , Línea Celular , Proliferación Celular/efectos de los fármacos , Citidina Desaminasa , Citoplasma/enzimología , Activación Enzimática , Productos del Gen vif/metabolismo , Genes env/genética , Infecciones por VIH/virología , VIH-1/genética , VIH-1/crecimiento & desarrollo , Humanos , Activación de Linfocitos/efectos de los fármacos , Mitógenos/farmacología , Datos de Secuencia Molecular , Peso Molecular , Complejos Multiproteicos/metabolismo , Nucleósido Desaminasas , Especificidad de Órganos , Proteínas/química , Proteínas/genética , Interferencia de ARN , Proteínas Represoras , Ribonucleasas/metabolismo , Ubiquitina/metabolismo , Replicación Viral/fisiología , Productos del Gen vif del Virus de la Inmunodeficiencia HumanaRESUMEN
We recently described a sensitive and specific assay that detects the fusion of HIV-1 virions to a broad range of target cells, including primary CD4 cells. This assay involves the use of virions containing beta-lactamase-Vpr (BlaM-Vpr) and the loading of target cells with CCF2, a fluorogenic substrate of beta-lactamase. Since Vpr strongly associates with the viral core, uncoating of the viral particle might be required for effective cleavage of CCF2 by BlaM-Vpr. Here, we show that BlaM-Vpr within mature viral cores effectively cleaves CCF2, indicating that this assay measures virion fusion independently of uncoating. We also show that wildtype and Nef-deficient HIV-1 virions fuse with equivalent efficiency to HeLa-CD4 cells, SupT1 T cells, and primary CD4 T cells. Since Nef enhances cytoplasmic delivery of viral cores and increases viral infectivity, these findings indicate that Nef enhances an early post-fusion event in the multistep process of viral entry. Possible sites of Nef action include enlargement of the fusion pore, enhanced uncoating of viral particles, and more efficient passage of viral cores through the dense cortical actin network located immediately beneath the plasma membrane.
Asunto(s)
Productos del Gen nef/fisiología , VIH-1/fisiología , Técnicas para Inmunoenzimas/métodos , Lactamas , Fusión de Membrana , Línea Celular , Citoplasma/virología , Fluoresceínas , Productos del Gen nef/deficiencia , Productos del Gen vpr/metabolismo , Proteína p24 del Núcleo del VIH/metabolismo , VIH-1/metabolismo , VIH-1/patogenicidad , Humanos , Especificidad por Sustrato , Virulencia , Replicación Viral , beta-Lactamasas , beta-Lactamas , Productos del Gen nef del Virus de la Inmunodeficiencia Humana , Productos del Gen vpr del Virus de la Inmunodeficiencia HumanaRESUMEN
The human immunodeficiency virus type 1 (HIV-1) relies on Vif (viral infectivity factor) to overcome the potent antiviral function of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, also known as CEM15). Using an APOBEC3G-specific antiserum, we now show that Vif prevents virion incorporation of endogenous APOBEC3G by effectively depleting the intracellular levels of this enzyme in HIV-1-infected T cells. Vif achieves this depletion by both impairing the translation of APOBEC3G mRNA and accelerating the posttranslational degradation of the APOBEC3G protein by the 26S proteasome. Vif physically interacts with APOBEC3G, and expression of Vif alone in the absence of other HIV-1 proteins is sufficient to cause depletion of APOBEC3G. These findings highlight how the bimodal translational and posttranslational inhibitory effects of Vif on APOBEC3G combine to markedly suppress the expression of this potent antiviral enzyme in virally infected cells, thereby effectively curtailing the incorporation of APOBEC3G into newly formed HIV-1 virions.
Asunto(s)
Productos del Gen vif/metabolismo , Infecciones por VIH/virología , VIH-1/metabolismo , Biosíntesis de Proteínas , Replicación Viral/fisiología , Desaminasa APOBEC-3G , Citidina Desaminasa , Citoplasma/metabolismo , Regulación hacia Abajo/fisiología , Inhibidores Enzimáticos/farmacología , Productos del Gen vif/genética , Infecciones por VIH/genética , Infecciones por VIH/inmunología , VIH-1/genética , VIH-1/patogenicidad , Humanos , Péptidos y Proteínas de Señalización Intracelular , Células Jurkat , Nucleósido Desaminasas , Péptido Hidrolasas/metabolismo , Unión Proteica/fisiología , Biosíntesis de Proteínas/genética , Procesamiento Proteico-Postraduccional , Proteínas/genética , Proteínas/metabolismo , ARN Mensajero/genética , Proteínas de Unión al ARN , Proteínas Represoras , Virión/genética , Virión/metabolismo , Productos del Gen vif del Virus de la Inmunodeficiencia HumanaRESUMEN
The nef gene products encoded by human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus type 1 (SIV-1) increase viral loads in infected hosts and accelerate clinical progression to AIDS. Nef exhibits a spectrum of biological activities, including the ability to downregulate surface expression of CD4 and major histocompatibility complex (MHC) class I antigens, to alter the state of T-cell activation, and to enhance the infectivity of viral particles. To determine which of these in vitro functions most closely correlates with the pathogenic effects of Nef in vivo, we constructed recombinant HIV-1 NL4-3 viruses carrying mutations within the nef gene that selectively impair these functions. These mutant viruses were evaluated for pathogenic potential in severe combined immunodeficiency (SCID) mice implanted with human fetal thymus and liver (SCID-hu Thy/Liv mice), in which virus-mediated depletion of thymocytes is known to be Nef dependent. Disruption of the polyproline type II helix (Pxx)4 within Nef (required for binding of Hck and p21-activated kinase-like kinases, downregulation of MHC class I, and enhancement of HIV-1 infectivity in vitro but dispensable for CD4 downregulation) did not impair thymocyte depletion in virus-infected Thy/Liv human thymus implants. Conversely, three separate point mutations in Nef that compromised its ability to downregulate CD4 attenuated thymocyte depletion while not diminishing viral replication. These findings indicate that the functional ability of Nef to downregulate CD4 and not MHC class I downregulation, Hck or PAK binding, or (Pxx)4-associated enhancement of infectivity most closely correlates with Nef-mediated enhancement of HIV-1 pathogenicity in vivo. Nef-mediated CD4 downregulation merits consideration as a new target for the development of small-molecule inhibitors.